Monday, July 30, 2007
P114
AMR-BAC-1, A Potent Natural Product-Derived Inhibitor of Gram Positive Pathogens
K. Romari, C. C. Smith, J. D. Rabenstein, D. C. Hopp, R. Newell, and G. J. Carr. AMRI, 18804 North Creek Parkway South, Bothell, WA 98011
Background: AMR-BAC-1 is a very potent antibacterial compound produced by an actinomycete strain from the AMRI Strain Collection. This study aimed at evaluating the in vitro activity of AMR-BAC-1 and other standard antibiotics against a panel of Gram-positive and Gram-negative pathogens. Also, we assessed the bactericidal activity of AMR-BAC-1 by time-kill methods against methicillin-resistant Staphylococcus aureus (MRSA) in comparison with vancomycin and linezolid.
Methods: Organisms used in this study included strains from the ATCC collection and clinical isolates. AMR-BAC-1 was tested for its activity by MIC and time-kill kinetics in accordance with CLSI guidelines.
Results: AMR-BAC-1 exhibited sub-µg/ml activity against all staphylococci and streptococci tested, with MICs ranging from 0.008 to 0.06 µg/mL. In vitro activity against Gram-negative pathogens ranged from 0.12 to 64 µg/mL. AMR-BAC-1 exhibited a dose-dependent bactericidal effect against MRSA with a sustained effect at 8X MIC (0.064 µg/mL) after 6 h.
Conclusion: AMR-BAC-1 is a potent antibacterial agent that shows concentration-dependent bactericidal activity against methicillin-resistant Staphylococcus aureus.
See more of Poster Session 2
See more of Posters
See more of The Annual Meeting and Exhibition 2007 (July 29 - August 2, 2007)
See more of Posters
See more of The Annual Meeting and Exhibition 2007 (July 29 - August 2, 2007)